Protheragen Announces Microneedle Technology Services to Accelerate Transdermal Drug Delivery Innovation
New York/US – September 29, 2026 – Protheragen has advanced its integrated microneedle technology solutions, delivering end‑to‑end custom services including formulation development and material selection & characterization for pharmaceutical enterprises, cosmetic companies, and related industry partners. The service portfolio covers multiple mainstream microneedle formats, including coated microneedle development, dissolving microneedle, hollow microneedle, hydrogel‑forming microneedle, and solid microneedle, to satisfy diversified transdermal drug delivery demands for small‑molecule compounds, proteins, nucleic acids, and other active substances.
Microneedle technology is an innovative transdermal drug delivery system that employs micron‑scale needles to pierce the stratum corneum and deliver therapeutic agents to targeted skin depths to join local microcirculation. By bypassing gastrointestinal digestion and first‑pass metabolism, this technology improves drug bioavailability, enables localized therapy to lower systemic adverse‑reaction risks, and supports sustained or controllable drug release through structural tuning of microneedle arrays.
Within its full‑scope microneedle technology solutions, Protheragen offers specialized coated microneedle development services for surface‑loaded delivery systems. Coated microneedles feature solid sharp substrates covered by drug‑containing soluble coating layers; once inserted into skin, interstitial fluid dissolves excipients in coatings, releasing payloads into target tissues. Protheragen supports multiple coating approaches, including masked dip coating, inkjet printing, immersion coating and, spray coating. Its service portfolio includes coating‑formulation development, microneedle geometric design, coating‑material screening, process optimization, delivery performance evaluation, and safety compatibility assessment, to secure uniform drug distribution, preserved drug bioactivity, and expected release profiles.
Meanwhile, the dissolving microneedle platform constitutes another core offering under Protheragen’s service suite. Dissolving microneedles embed active pharmaceutical ingredients within biodegradable polymer matrices. After skin application, the whole needle body dissolves completely inside tissue, generating no sharp biohazard waste and enabling pain‑free self‑administration. Protheragen leverages PDMS‑mold‑based fabrication workflows, together with a broad selection of matrix materials such as carboxymethyl chitosan, PVP, PVA, and PLGA. Its dissolving microneedle services span structural design, prototyping, formulation optimization, analytical testing covering mechanical strength, dissolution kinetics, and biocompatibility, as well as regulatory document support for clients from the pharmaceutical and cosmetic sectors.
Backed by cross‑disciplinary teams of scientists and engineers, Protheragen’s microneedle technology services run through the whole R&D pipeline: initial concept design, prototype preparation, material characterization, formulation optimization, preclinical and clinical evaluation, manufacturing scale‑up, and post‑commercialization technical support. Protheragen maintains collaborative links with global pharmaceutical firms, medical‑device manufacturers, and research institutes to keep pace with cutting‑edge microneedle research progress.
About Protheragen
Protheragen provides comprehensive, tailor‑made drug delivery development services for various advanced delivery technologies, supporting partners to overcome technical bottlenecks in drug permeability, stability, and administration mode. Whether clients are in the pharmaceutical industry, medical research, or a related field, its team of experts is ready to support researchers’ novel drug delivery development needs.
Media Contact
Company Name: Protheragen
Contact Person: Hannah Green
Email: Send Email
Country: United States
Website: https://www.protheragen.ai/
